Erufosine, a phosphoinositide-3-kinase inhibitor, to mitigate posterior capsule opacification in the human capsular bag model.
Wertheimer C, Brandlhuber U, Kook D, Mayer WJ, Laubichler P, Wolf A, Kampik A, Eibl-Lindner K.
Wertheimer C, et al. Among authors: kampik a.
J Cataract Refract Surg. 2015 Jul;41(7):1484-9. doi: 10.1016/j.jcrs.2015.02.034. Epub 2015 Jul 22.
J Cataract Refract Surg. 2015.
PMID: 26210048
The tissue was exposed to the half maximum inhibitory concentrations of erufosine alone for 72 hours; solvent-only tissue served as a control. Erufosine is a potent inhibitor of phosphoinositide-3-kinase, a downstream kinase with major implications in posteri …
The tissue was exposed to the half maximum inhibitory concentrations of erufosine alone for 72 hours; solvent-only tissue served as a …